Syniverse Holdings (SVR) 30.99 0.00

Syniverse Holdings, Inc.
(SVR) 30.99 0.00

Last Trade:	30.98	Day Range:	30.98 - 30.98
Trade Time:	Jan 12	52wk Range:	0.00 - 0.00
Prev. Close:	30.98	Market Cap:	2.18B
Open:	30.98	Div Yield:	0
Volume:	0	PE:	260
EPS:	1.17

The Latest On SVR

Merck Reports Phase III Study Results Evaluating Anaemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy 4/19/12 7:00am

Piper Jaffray Reiterates Overweight, $90 PT on Pharmasset 11/15/11 11:07am

Piper Jaffray Overweight on Pharmasset 11/7/11 8:35am

Biotech and Pharma Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request for Hemopurifier® Investigational Device Exemption (IDE) 5/10/11 1:57pm

Biotech/Biodefense Stock News; Aethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV) 5/9/11 11:49am

Piper Jaffray Comments On Vertex Pharmaceuticals' Phase III REALIZE Results 4/1/11 7:30am

Merger Arbitrage Mondays – January 17, 2011 1/17/11 2:40am

Syniverse Stockholders Approve Merger with The Carlyle Group 1/12/11 1:00pm

Syniverse Granted Early Termination of HSR Waiting Period for Merger with The Carlyle Group Affiliate 11/30/10 11:34am

Syniverse Beats Zacks Consensus - Analyst Blog 11/4/10 2:33pm

Syniverse Reports Strong Third Quarter Results: EPS of $0.33 11/2/10 4:12pm

Afternoon Market Update (MCO, SVR, CELG) 10/28/10 12:08pm

Merck Reports Phase III Study Results Evaluating Anaemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy 4/19/12

Piper Jaffray Reiterates Overweight, $90 PT on Pharmasset 11/15/11

Piper Jaffray Overweight on Pharmasset 11/7/11

Biotech and Pharma Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request for Hemopurifier® Investigational Device Exemption (IDE) 5/10/11

Biotech/Biodefense Stock News; Aethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV) 5/9/11

Piper Jaffray Comments On Vertex Pharmaceuticals' Phase III REALIZE Results 4/1/11

Merger Arbitrage Mondays – January 17, 2011 1/17/11

Syniverse Stockholders Approve Merger with The Carlyle Group 1/12/11

Syniverse Granted Early Termination of HSR Waiting Period for Merger with The Carlyle Group Affiliate 11/30/10

Syniverse Beats Zacks Consensus - Analyst Blog 11/4/10

Syniverse Reports Strong Third Quarter Results: EPS of $0.33 11/2/10

Afternoon Market Update (MCO, SVR, CELG) 10/28/10

Biotech and Pharma Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request for Hemopurifier® Investigational Device Exemption (IDE) 5/10/11

Biotech/Biodefense Stock News; Aethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. Treatment Indications to Include Hepatitis C Virus (HCV) 5/9/11

Top Narrow Based Indexes For October 28 (SVR, EK, HMA) 10/28/10

JP Morgan: Channel Checks On SVR Positive 6/30/10

A Peek Into The Market At The Start Of The Trading Day 6/29/10

SVR’s Roaming And Messaging Show Positive Gains 5/10/10

Piper Jaffray Reiterates Overweight, $90 PT on Pharmasset 11/15/11

Piper Jaffray Overweight on Pharmasset 11/7/11

Piper Jaffray Comments On Vertex Pharmaceuticals' Phase III REALIZE Results 4/1/11

Upgrades From RBC Capital Markets 10/5/10

Oppenheimer Sees Positive Trends For Syniverse (SVR) 9/27/10

Oppenhiemer Sees 14% Upside In Syniverse Holdings 9/22/10

Goldman Remains Buy On Syniverse Technologies, Inc. (SVR) 8/5/10

Jefferies Raising Price Target On Syniverse (SVR) 8/3/10

Syniverse Delivers Good Quarter, Deutsche Bank Ups Price Target (SVR) 8/3/10

JP Morgan: Channel Checks On SVR Positive 6/30/10

A Peek Into The Market At The Start Of The Trading Day 6/29/10

Oppenheimer Reaffirms Syniverse Outperform Rating (SVR) 6/29/10

Trade SVR
NOW!

Partner Headlines

Syniverse Holdings Inc. Reports Operating Results (10-K) 3/7/12

5 Ways To Buy Precious Metals Now 1/27/12

Syniverse Holdings Inc. Reports Operating Results (10-Q) 11/9/11

Press Releases

Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy 4/19/12 Business Wire

For the Treatment of Hepatitis C Virus, the Majority of Surveyed U.S. Physicians Who Prescribe Vertex's Incivek More Often Than Merck/Roche's Victrelis Perceive Incivek as Offering a Short, Simple and Highly Efficacious Treatment Option 4/5/12 Business Wire

Adept Technology Celebrates Third Annual National Robotics Week 4/4/12 GlobeNewswire

Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 3/6/12 Business Wire

Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12) 3/6/12 Business Wire

Aethlon Medical to Present Hepatitis C (HCV) Treatment Technology at the 32nd Annual Dialysis Conference 2/7/12 Newswire

Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol 2/1/12 Newswire

The Contractor Mortgage Company Reports Increase in Remortgage Enquiries 1/27/12 PRWeb

Bristol-Myers Squibb Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of Strategic Transactions and Good Operating Performance 1/27/12 Business Wire

Get the latest SVR stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Syniverse Holdings, Inc. stock price.

Syniverse Holdings, Inc. by YCharts

Syniverse Holdings (SVR) 30.99 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On SVR

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social